Wednesday February 21st 2018

[Comment] Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain

In 2009, Zamboni and colleagues reintroduced the theory that obstructions of the venous outflow from the CNS are associated with multiple sclerosis, and they proposed a link with multiple sclerosis pathogenesis. This hypothesis, originally posed by Putnam in 1947, then attracted an enormous amount of attention from patients, physicians, and the media, but also caused substantial uncertainty. In fact, both the theory and the ultrasound and catheter venography studies on which the concept of chronic cerebrospinal venous insufficiency is based have substantial methodological flaws, as has recently been shown convincingly. (Source: LANCET)

View post: 

[Comment] Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain

Leave a Comment

More from category

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]

Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…
Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…

Subtle gait and balance dysfunction is a precursor to loss of mobility in multiple sclerosis (MS). Biomechanical [Read More]

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]